Literature DB >> 8999920

Production and characterization of recombinant human plasminogen(S741C-fluorescein). A novel approach to study zymogen activation without generation of active protease.

A J Horrevoets1, H Pannekoek, M E Nesheim.   

Abstract

A variant of recombinant plasminogen with the plasmin active site serine (S741) replaced by cysteine was produced and labeled with fluorescein at this residue to provide the derivative Plg(S741C-fluorescein). Studies of cleavage, conformation, and fibrin-binding properties of the derivative showed it to be a good model substrate to study plasminogen activation. Both in solution and in a fully polymerized fibrin clot, cleavage of the single chain zymogen to the two-chain "plasmin" molecule was accompanied by a 50% quench of fluorescence intensity. This change allows facile, continuous monitoring of the kinetics of cleavage. Measurements of cleavage by single chain t-PA within intact, fully polymerized 3 microM fibrin yielded apparent kcat and Km values of (0.08 s-1, 0.52 microM) and (0.092 s-1, 0.098 microM) for [Glu1]- and [Lys78]Plg(S741C-fluorescein), respectively. These values are similar to those obtained by others with plasma plasminogen. The approach used here might generally be useful in simplifying the analysis of zymogen activation kinetics in cases where the product (protease) has a great influence on its own formation via positive or negative feedback loops.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8999920     DOI: 10.1074/jbc.272.4.2176

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A.

Authors:  J H Foley; M E Nesheim; G E Rivard; K E Brummel-Ziedins
Journal:  Haemophilia       Date:  2011-09-20       Impact factor: 4.287

2.  Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis.

Authors:  Jonathan H Foley; Paula Kim; Michael E Nesheim
Journal:  J Biol Chem       Date:  2008-02-05       Impact factor: 5.157

3.  Reduced plasminogen binding and delayed activation render γ'-fibrin more resistant to lysis than γA-fibrin.

Authors:  Paul Y Kim; Trang T Vu; Beverly A Leslie; Alan R Stafford; James C Fredenburgh; Jeffrey I Weitz
Journal:  J Biol Chem       Date:  2014-08-15       Impact factor: 5.157

4.  The generation and characterization of mice expressing a plasmin-inactivating active site mutation.

Authors:  T Iwaki; C Malinverno; D Smith; Z Xu; Z Liang; V A Ploplis; F J Castellino
Journal:  J Thromb Haemost       Date:  2010-10       Impact factor: 5.824

5.  Kinetics of activated thrombin-activatable fibrinolysis inhibitor (TAFIa)-catalyzed cleavage of C-terminal lysine residues of fibrin degradation products and removal of plasminogen-binding sites.

Authors:  Jonathan H Foley; Paul F Cook; Michael E Nesheim
Journal:  J Biol Chem       Date:  2011-04-05       Impact factor: 5.157

6.  Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates fibrin-dependent plasmin generation on thrombin-activated platelets.

Authors:  Ran Ni; Miguel A D Neves; Chengliang Wu; Samantha E Cerroni; Matthew J Flick; Heyu Ni; Jeffrey I Weitz; Peter L Gross; Paul Y Kim
Journal:  J Thromb Haemost       Date:  2020-09       Impact factor: 5.824

Review 7.  The ANXA2/S100A10 Complex-Regulation of the Oncogenic Plasminogen Receptor.

Authors:  Alamelu G Bharadwaj; Emma Kempster; David M Waisman
Journal:  Biomolecules       Date:  2021-11-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.